The US Food and Drug Administration (FDA) has granted Fast Track Designation to SNB-101 for small cell lung cancer (SCLC), according to a news release from SN Bioscience Co. Ltd, the manufacturer of the drug. “SNB-101 was designated as an orphan drug for [SCLC] and pancreatic cancer in July of last year and February of this year, respectively,” company officials said in the news release. “By receiving Fast Track Designation this time, it is evaluated that it has laid the groundwork that can be commercialized immediately after completion of phase 2 ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
Breastfeeding may reduce the impact of maternal smoking on lung cancer mortality in adult offspring.
The primary end point of the RESILIENT trial was OS.
State tobacco quitlines are "uniquely positioned to inform smokers about radon."
The approval is based on results from the phase 3 ALINA study.
DNA methylation patterns may lend clues to the elusive etiology of lung cancer in people who have never smoked.
Dr. Marisa Bittoni discusses the possible link between vaping and lung cancer risk.
Role of MicroRNAs on Anti-Apoptotic MCL-1/cIAP-2 Gene Expression in Patients With EGFR-Mutated NSCLC
A study that assessed the impact of miR-29a and miR-143 on gene expression in lung cancer.
Patient-derived organoids have shown promise in modeling cancer therapy response.
A study that examined whether the combination of AI and knowledge can identify more patients with lung and ovarian cancers.
A study detailed the landscape of lung adenocarcinoma progression.
Advertisement
Expert Interviews on Lung Cancer
Conference Coverage
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
